EGFR and cancer: Ultimately, this highly specific treatment strategy that includes cancer‐specific target gene SOX2 with functional anti‐EGFR tLNPs holds great promise for safe and efficient CRISPR treatment HNC, and ultimately for many other palpable solid cancers.